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Abstract 
Advanced drug delivery systems often employ nanomaterials as carriers to deliver drugs to 
desirable disease sites for enhanced efficacy. However, most systems have low drug loading 
capacity and cause safety concerns. Therefore, many anticancer therapeutics have recently 
been assembled to NPs form without using any additional nanocarrier to achieve high drug 
loading. However, carrier-free nanomedicines are often constrained by limitations such as 
inadequate stability and lack of control in drug release. Therefore, we synthesize carrier-free 
drug NPs containing cis-aconitic anhydride-modified doxorubicin and paclitaxel (CAD-PTX) 
and coating with crosslinked (CL) surfactant based on hyaluronic acid (HA) segment. With 
this design, the pure drug NPs possess pH and redox dual responsive release characteristic 
and could target CD44 overexpressed cancer cells. Our studies demonstrate that these 
CAD-PTX-CLHA NPs display high stability, excellent active targeting effect and 
controllable intracellular drug release, and ultimately achieve significantly better anti-cancer 
efficiency than individual doxorubicin and paclitaxel. 
Keywords: Nanomedicine, pH-responsive, GSH-responsive, targeted delivery, synergistic 
therapy 
Background 
In the past a few decades, the development of nanotechnology has offered abundant 
opportunities for cancer therapy.
1-5
 Nano-drug delivery systems have shown many 
superiorities compared to traditional anticancer drugs, such as controlled delivery and release, 
improved water-solubility, bioavailability, stability, and tumor selectivity, as well as reduced 
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side effects.
6-12
 Recently, pure anticancer drug nanoparticles (NPs) have been synthesized as 
a new pattern of nanomedicine, which first involves assembling pure hydrophobic drugs into 
NPs, followed by stabilizing with surfactants for good water dispersity and high 
biostability.
13
 These pure therapeutic NPs have high drug loading capacity and alleviate the 
potential systemic toxicity caused by accumulation of excipient nanocarriers such as gold 
and silica NPs for drug delivery.
14
 However, at the current stage, the reported pure drug NPs 
often possess inadequate in vivo stability and less control of drug release depending on 
environment.
15
 Therefore, we aim to develop environmentally responsive pure drug 
nanomedicine with high stability for enhanced anticancer therapy. Because of the unique pH 
and redox environment of tumor tissues and intracellular compartments, we decide to adopt 
pH and redox as the stimuli. In detail, the pH value of normal physiological condition is ~7.4, 
which is higher than that of tumor tissues (~6.8); the pH values of intracellular endosome 
and lysosome (pH 5.0-6.5) are significantly lower than those of extracellular 
microenvironment.
16-18
 Meanwhile, glutathione (GSH) is a thiol containing tripeptide and 
has high concentration in cells (~ 10 mM), much higher than that of the extracellular 
environment (~2 µM).
19
 GSH can exist in reduced state and oxidized state and therefore 
provides a redox environment. Therefore, joint pH and redox responsive drug delivery 
systems have been widely developed for controllable anticancer therapy. 
With this idea, we design to synthesize pH-responsive cis-aconitic anhydride 
(CA)-modified doxorubicin (DOX) (CAD) and paclitaxel (PTX) NPs, followed by coating 
with a layer of GSH-responsive crosslinked surfactant based on sodium hyaluronic acid 
(HA). In the design, DOX and PTX molecules are conjugated via a pH-responsive linker CA. 
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Since DOX and PTX have different inhibition mechanisms and antitumor targets, the 
combination will greatly enhance therapeutic efficacy and better overcome multidrug 
resistance (MDR).
20-26
 HA is able to target cancer cells with overexpression of CD44 
receptor such as human breast adenocarcinoma cells and human lung cancer cells.
27-30
 
Moreover, redox induced fragmentation of disulfide bonds in HA crosslinking would 
consume intracellular GSH, generate cellular reactive oxygen species (ROS), and finally 
induce MCF-7/ADR cell apoptosis.
31-34
 To confirm these NPs’ pH- and redox-responsive 
characteristics and their efficiency in anticancer therapy, we systematically investigate their 
physical and chemical properties, and study the in vitro and in vivo applications. 
Methods 
Materials, characterization, synthesis of CAD and SAD, synthesis of CAD-PTX and 
SAD-PTX, synthesis of Cysm-HA-C18n are described in Supplementary Material. 
Preparation and modification of CAD-PTX NPs and SAD-PTX NPs 
CAD-PTX NPs were prepared by a solvent exchange method. CAD-PTX was dissolved 
in DMF and then the solution was dropwisely added into water under vigorous stirring, 
followed by dialysis against deionized water to obtain CAD-PTX NPs. Then 200 µL of 1.0 
mg mL
-1 
Cysm-H -C18n aqueous solution were added to the solution of CAD-PTX NPs. The 
mixture was then ultrasonicated for 5 min followed by 1 h incubation at room temperature to 
obtain CAD-PTX NCLHA NPs. To obtain NPs with crosslinked surfactants on the surface, 
the pH of CAD-PTX NCLHA NPs solution was adjusted to be 8.5 followed by 12 h 
incubation. SAD-PTX NCLHA NPs and SAD-PTX CLHA NPs were prepared with the same 
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method. 
Stability 
The stability of CAD-PTX NCLHA NPs, CAD-PTX CLHA NPs, SAD-PTX NCLHA 
NPs and SAD-PTX CLHA NPs was studied by using DLS to measure their size evolution in 
phosphate buffered solution (PBS) and fetal bovine serum (FBS) at different periods of 
storage. Three samples were measured in each group, and the measurements were performed 
in triplicate and the average was used in analysis. 
In vitro release of DOX from NPs 
The release of DOX from CAD-PTX-CLHA NPs were studied by placing 4 samples in 
separate dialysis cartridges with a 14 kDa MWCO, followed by dialysis against 100 mL of 
PBS/FBS (10 mM, pH 7.4), 100 mL PBS/FBS (10 mM, pH 7.4) with 10 mM DTT, 100 mL 
PBS/FBS (10 mM, pH 5.0), and 100 mL PBS/FBS (10 mM, pH 5.0) with 10 mM DTT at 
37 °C. To determine the release, 1 mL of PBS/FBS solution was collected to measure the 
fluorescence of DOX. Each time after sample collection, 1 mL of fresh dialysis medium was 
added to each group to keep the total volume constant. Three samples were measured in each 
group, and the measurements were performed in triplicate and the average was used in 
analysis. 
Cell culture 
Human cervical (HeLa) cells, human embryonic kidney (HEK-293T) cells and human 
lung carcinoma (A549) cells were cultured in Dulbecco's Modified Eagle's medium 
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(DMEM), while murine 4T1 breast cancer (4T1) cells, human mammary carcinoma (MCF-7) 
cells and DOX resistant human mammary carcinoma (MCF-7/ADR) cells were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% of fetal bovine 
serum (FBS) and antibiotics in a humidified atmosphere containing 5% CO2 at 37 °C. 
In vitro cytotoxicity of NPs 
The cytotoxicities of CAD-PTX-CLHA NPs and SAD-PTX-CLHA NPs were examined 
with a MTT assay towards HEK-293T and A549 cells. The cells pre-treated with HA 
polymer (5 mg/mL) for 4 h were set as control. The cells were seeded in 96-well plates at 6.0 
×10
4
 cells per well in 80.0 μL of complete media, and then incubated at 37 °C in 5% (v/v) 
CO2 for 24 h. The drug concentrations of CAD-PTX-CLHA NPs were ranged from 2.5 to 40 
μM (2.5, 5, 10, 20 and 40 μM). The drug concentration (DC) was defined as the sum 
concentration of DOX and PTX in each well. After incubation for another 24 h and 48 h, the 
standard MTT assay was performed to determine the viability of cells. Six cell samples were 
measured in each group for averaged calculation. 
Subsequently, the cytotoxicities of DOX·HCl, PTX, DOX+PTX mixture, 
CAD-PTX-NCLHA NPs, CAD-PTX-CLHA NPs, SAD-PTX-NCLHA NPs and 
SAD-PTX-CLHA NPs towards HeLa and 4T1 cells were measured. Samples were added to 
each well with a drug concentration from 2.5 to 40 μM (2.5, 5, 10, 20 and 40 μM). In a 
separate experiment, the inhibition effect of multidrug resistance was examined with a MTT 
assay towards MCF-7/ADR cells expressing a high level of CD44 receptors. DOX·HCl, 
DOX+PTX mixture and CAD-PTX-CLHA NPs were added to each well. The DC was 2.5, 5, 
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10, 20 and 40 μM in different groups. In another experiment, the cells were pre-treated with 
HA polymer (5 mg/mL) for 4 h, then CAD-PTX-CLHA NPs of different concentrations were 
added to each well. Six cell samples were measured in each group for averaged calculation. 
In vitro cellular uptake 
The intracellular distribution of CAD-PTX-CLHA NPs in HeLa cells was observed 
using confocal laser scanning microscopy (CLSM). HeLa cells were seeded in a 24-well 
plate at a density of 1.0 × 10
5
 cells per well in 0.8 mL of complete media and incubated for 
12 h. Next, 200 μL of CAD-PTX-CLHA NPs were added to each well (5.0 μM of DOX). 
After cells were incubated with CAD-PTX-CLHA NPs for different times (4, 6, 12 and 24 h). 
Hoechst 33258 and Lyso-Tracker Green (Beyotime, Shanghai agent, China) were used to 
stain the nuclei and lysosome of cells for 30 min under 5% CO2, respectively. Finally, the 
cells were washed with PBS for three times and studied using a Leica laser scanning 
confocal microscope. 
The cellular uptake of CAD-PTX-CLHA NPs were studied in MCF-7/ADR cells using 
both CLSM and flow cytometry. In the experiment, 200 μL of DOX·HCl or 
CAD-PTX-CLHA NPs were added to each well (5.0 μM of DOX), followed by incubation at 
37 °C for 6 and 12 h. Then the cells were washed with PBS for three times and stained with 
Lyso-Tracker Green for 30 min under 5% CO2 at 37 °C. Finally, the cells were again washed 
with PBS for three times for confocal fluorescence microscopy imaging. Additionally, extra 
groups of cells treated with the same way as above were trypsinized for flow cytometry 
analysis. For both CLSM and flow cytometry analysis, the inhibition experiments were also 
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performed by pre-treating MCF-7/ADR cells with free HA (5 mg/mL) for 4 h prior to 
incubating with CAD-PTX-CLHA NPs. 
Detection of ROS 
MCF-7/ADR cells were treated with blank cell culture medium and medium containing 
DOX·HCl, PTX, DOX+PTX mixture, and CAD-PTX-CLHA NPs under 5% CO2 at 37 °C. 
After 12 and 24 h incubation, the culture medium was removed and the cells were washed 
with PBS for two times, followed by staining with DCFH-DA (Beyotime, Shanghai agent, 
China) for 20 min under 5% CO2 at 37 °C for confocal fluorescence microscopy. The total 
concentrations of DOX and PTX in all groups were 10 μM.  
In vivo blood circulation of CAD-PTX-CLHA NPs 
To know the blood circulation of CAD-PTX-CLHA NPs, samples were injected into 
BALB/c mice via intravenous tail vein injection (200 μL, 1 mg/mL). At each desirable time 
point after injection, ~10 μL of blood was collected, followed by dissolving in 1 mL of lysis 
buffer (1% SDS, 1% Triton X-100, 40 mM Tris acetate) to measure the fluorescence 
intensity of DOX. Five mice were measured in each group for averaged calculation. 
Biodistribution of CAD-PTX-CLHA NPs 
The biodistribution of CAD-PTX-CLHA NPs after intravenous injections were 
qualitatively or semiquantitatively assessed by ex vivo CAD-PTX fluorescence imaging of 
major internal organs. In detail, tumor bearing mice were prepared by inoculating 
MCF-7/ADR cells into BALB/c mice. When the tumor volume increased to about 50 mm
3
, 
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200 μL of CAD-PTX-CLHA NPs (1 mg/mL) were intravenously injected to mice though tail 
vain. The mice were sacrificed at different time intervals (2, 6, 12 and 24 h), and the major 
organs including heart, liver, spleen, lung, kidney, stomach, intestine and tumor were excised 
for fluorescence imaging. The background signal and autofluorescence of individual tissues 
and organs of untreated mice were used as a reference. Three mice were measured in each 
group for averaged calculation. 
In vivo imaging 
The hair of MCF-7/ADR tumor-bearing mice was removed from neck to foot, followed 
by intravenous injection of 200 µL of 1 mg/mL CAD-PTX-CLHA NPs. After 24 h, the mice 
were imaged using a Maestro in vivo fluorescence imaging system (CRi Inc.), using a 488 
nm laser as the excitation source. In vivo spectral imaging (10 nm step) was carried out from 
520 to 650 nm for the mice. 
In vivo antitumor activity 
Individual groups of MCF-7/ADR tumor-bearing mice were separately treated with 200 
μL of PBS, and 1 mg/ml of DOX·HCl, PTX, DOX+PTX mixture and CAD-PTX-CLHA 
NPs. A boost injection was given at 7 days after the primary injection. The tumor size and 
weight of each mouse were measured daily for 2 weeks. Relative tumor size and weight were 
calculated to be the ratio of tumor volume and weight over the initial values, respectively, 
immediately before the primary treatment. All animal experiments were performed with the 
approval of Soochow University Laboratory Animal Center and the Animal Care and Use 
Committee of Soochow University. Six mice were measured in each group for averaged 
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calculation. 
Results 
Synthesis and characterization of CAD-PTX, SAD-PTX and Cys7-HA-C184 
To develop pH-responsive dimeric drug molecules, DOX and PTX were 
conjugated via CA as the bridge to produce CAD-PTX. The synthetic route is depicted 
in Figure 1, A. Due to the influence of the ɑ-ethylenic bond, the amide bond between 
DOX and CA is pH-responsive. For comparison, SAD-PTX molecules conjugated by 
SA were also developed (Figure S1) to be responsive to pH values. The 
1
H NMR 
spectrum of CAD (Figure S2, A) displays signals at 6.28 ppm attributed to the hydrogen 
proton in CA, while the signals at 2.31-2.37 ppm in the 
1
H NMR spectrum of SAD 
(Figure S2, B) can be attributed to the hydrogen proton in SA. Moreover, the signals of 
the hydrogen protons in DOX and PTX are shown in the 
1
H NMR spectra of CAD-PTX 
and SAD-PTX, respectively. 
To allow drug NPs to be responsive to redox environment, a surfactant was 
synthesized containing hydrophobic segments (C18), crosslinkable cysteine (Cys) and 
hydrophilic HA, termed Cysm-HA-C18n. HA is redox responsive and can effectively 
target the CD44 receptor overexpressing on cancer cells. The synthetic route of 
Cysm-HA-C18n is illustrated in Figure 1, B. The 
1
H NMR spectrum of Cysm-HA-C18n 
is shown in Figure S3. The 
1
H NMR spectrum exhibits clear signals attributable to Cys 
moieties (δ 2.56, 3.12-3.18), C18 segments (1.22) and HA backbone (δ 1.93, 3.25-3.95, 
4.50). The degree of substitution (DS) is defined as the number of C18 or Cys units per 
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100 sugar residues of HA polymer. The DS of C18 could be determined by calculating 
the integrals of signals at δ 1.22 (methylene protons of Lys) and δ 4.50 (anomeric 
proton in HA). Herein, the DS of C18 is 4, and the DS of Cys determined by Ellman’s 
test is 7. Thus, the molecular formula of our synthesized surfactant is Cys7-HA-C184.  
To enable Cys7-HA-C184 molecules to crosslink, the pH value of the solution was 
adjusted to be 8.5. The free thiol groups in the solution were determined by Ellman’s 
test. As shown in Figure 3, D, the absorbance of the free thiol groups in the solution (pH 
8.5) disappears after 12 h reaction. 
Preparation and characterization of NPs 
CAD-PTX NPs were synthesized via a solvent exchange method (Figure 2). 
Subsequently, Cys7-HA-C184 aqueous solution was added to CAD-PTX NPs 
suspension for surface coating. On these NPs, the surfactant molecules are not 
cross-linked (NCL), termed as CAD-PTX-NCLHA NPs. Our previous work has shown 
that NPs stability can be substantially enhanced when surfactant molecules are 
crosslinked, which will prevent premature release of drugs during blood circulation.
35
 
Therefore, to improve the stability of CAD-PTX-NCLHA NPs, Cys7-HA-C184 
molecules were cross-linked by adjusting the solution pH to be 8.5 followed by 12 h 
incubation. These NPs with crosslinked surfactant molecules are defined as 
CAD-PTX-CLHA NPs. As control groups, SAD-PTX NCLHA NPs and SAD-PTX 
CLHA NPs were also prepared with similar procedures. 
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The as-prepared NPs were observed with scanning electron microscopy (SEM) 
and transmission electron microscopy (TEM). The results indicate that CAD-PTX 
(Figure 3, A) and SAD-PTX (Figure S4, A) NPs are spherical and have relatively 
uniform size. The hydrodynamic sizes of the NPs were measured by DLS analysis 
and the results are shown in Figure 3, B and Figure S4. The average sizes of 
CAD-PTX and SAD-PTX NPs are approximately 90 nm. After surface modification 
with Cys7-HA-C184, the size of the NPs does not change much regardless of whether 
the surfactant molecules are crosslinked or not. The stability of these NPs in PBS and 
FBS is also studied (Figure 3, C, Figure S5 and Figure S6). Apparently, with 
Cys7-HA-C184 molecules coated on the surface of NPs, whether they are cross-linked 
or not, the surface-functionalized NPs both display good stability. We further measured 
the release rate of free DOX and CAD-PTX-CLHA NPs. As Figure S7 shown, DOX 
was rapidly released from free DOX, however, the drug release rate of 
CAD-PTX-CLHA NPs was significantly slower at neutral pH, confirming NPs’ 
stability in physiological environment.  
After synthesizing CAD-PTX-CLHA NPs, it is important to know their drug 
release profiles. As shown in Figure 3, E and F, within the first 10 h, no burst release is 
observed from both CAD-PTX-CLHA NPs and SAD-PTX-CLHA NPs, with only 
approximately 13% and 12% of DOX is released in PBS at pH 7.4, respectively. With 
decrease of pH values from 7.4 to 5.0, the cumulative DOX release amount of 
CAD-PTX-CLHA NPs is significantly accelerated to 34% within the same period, 
while that of SAD-PTX-CLHA NPs is only 15%. The burst release of DOX from 
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CAD-PTX-CLHA NPs at pH 5.0 may be due to the breakage of pH-sensitive linkage 
under acidic environment. 
Attractively, the release of DOX from CAD-PTX-CLHA and SAD-PTX-CLHA 
NPs can be boosted under a redox environment containing 10 mM DTT. Within the 
first 10 h, at pH 7.4, 30% and 28% of DOX is released from CAD-PTX-CLHA and 
SAD-PTX-CLHA NPs, respectively. Compared with the case without DTT, the DOX 
release from both types of NPs has been more than doubled. At pH 5.0 and 10 mM 
DTT, the release of DOX from CAD-PTX-CLHA NPs dramatically increases to 68% 
within the same period of time. In great contrast, under the same condition of pH and 
redox environment, only 30% of DOX is released from SAD-PTX-CLHA NPs. 
Furthermore, the drug release profiles of NPs in FBS solution are also investigated 
(Figure S8). Compared with FBS at pH 7.4, the release of DOX from 
CAD-PTX-CLHA NPs increases apparently at pH 5.0 and 10 mM DTT, which is 
consistent with that in PBS solutions. 
Cellular uptake and intracellular distribution of NPs 
After knowing the release profile of CAD-PTX-CLHA NPs, we further studied 
their intracellular release kinetics. As shown in Figure 4, at 4 h after HeLa cells being 
incubated with CAD-PTX-CLHA NPs, very weak red fluorescence of DOX can be 
observed in the cytoplasm. As time increases, by the 12 h time point, the fluorescence 
signal becomes stronger and gradually migrates to the nuclei region. After 24 h 
incubation, intense DOX fluorescence overlaps with the nuclei staining. These results 
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are possibly due to the behaviour that CAD-PTX-CLHA NPs release DOX in the acidic 
intracellular pathway compartments, and subsequently diffuse to the nuclei region.  
In vitro cytotoxicity of NPs 
To verify the targeting ability of CAD-PTX-CLHA NPs, HEK-293T normal cells 
expressing a low level of CD44 receptors, and A549 cancer cells overexpressing with 
CD44 receptors were chosen as model cells.
36 
Additionally, another group of A549 
cancer cells was pre-treated with HA for 4 hours and used as control group. As 
presented in Figure 5, A and B, CAD-PTX-CLHA NPs show time and dose dependent 
cytotoxicity to the tested three cell lines. At the highest concentration of 40 μM, 
CAD-PTX-CLHA NPs still exhibit low cytotoxicity (viability of 72%) against 
HEK-293T normal cells, but the cytotoxicity to A549 cancer cells is much higher, 
with a viability of 23%. Attractively, when A549 cancer cells was pre-treated with HA 
for 4 hours, CAD-PTX-CLHA NPs with the same concentration exhibit a much lower 
cytotoxicity (viability of 67%). The reason is that the surface CD44 receptors have 
been conjugated with HA in the pre-treatment. Therefore, the CAD-PTX-CLHA NPs 
were not able to effectively target these cells any more. Besides, the in vitro 
cytotoxicity of SAD-PTX-CLHA NPs are also measured. As shown in Figure S9, HA 
pre-treated A549 cancer cells prevents their internalization of SAD-PTX-CLHA NPs, 
further demonstrating that CAD-PTX-CLHA NPs targeting A549 cancer cells mainly 
through CD44. 
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To further explore the cancer cell killing effect, CAD-PTX-CLHA NPs of 
different drug concentrations ranging from 2.5 to 40 μM were incubated with HeLa and 
4T1 cells for 48 hours, followed by viability measurement (Figure 5, C and D, and 
Figure S10). DOX·HCl, PTX, DOX+PTX mixture, and CAD-PTX-NCLHA NPs were 
also tested under the same conditions for comparison. The concentrations were defined 
as the sum concentration of DOX and PTX in each sample. As shown in Figure 5, C, at 
the highest concentration of 40 μM, CAD-PTX-CLHA NPs have higher cytotoxicity 
(viability of only 10%) than all other reagents: the viabilities of DOX, PTX, and 
DOX-PTX, and CAD-PTX-NCLHA NPs treated cells are 21%, 26%, 23%, and 9%, 
respectively.  
Besides, at all concentrations, CAD-PTX NPs possess higher toxicity than 
SAD-PTX NPs, which may be resulted from the quick release of DOX from CAD-PTX 
NPs at acidic intracellular microenvironment (Figure 5, C and D, Figure S11 and S12). 
For example, at the highest drug concentration of 40 μM, CAD-PTX-CLHA NPs 
exhibit substantially higher cytotoxicity (viability of 10%) than SAD-PTX-CLHA NPs 
(viability of about 50-60%). 
To study the inhibition effect towards multidrug resistant cells, CAD-PTX-CLHA 
NPs were incubated with MCF-7/ADR cells, followed by viability examination. 
MCF-7 cells were also used in another group as control (Figure 5, E and F, Figure S13). 
At the highest drug concentration of 40 μM, CAD-PTX-CLHA NPs possess similar 
toxicity against MCF-7 cells with DOX and DOX+PTX mixture. However, when 
incubated with MCF-7/ADR cells, CAD-PTX-CLHA NPs exhibit apparently higher 
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toxicity than free drug groups, indicating their effective efficacy in killing multidrug 
resistant cells. The targeting performance of CAD-PTX-CLHA NPs towards 
MCF-7/ADR cells which express a high level of CD44 receptors was also investigated. 
After being pre-treated with HA polymer (5 mg/mL) for 4 h, MCF-7/ADR cells were 
incubated with different concentrations of CAD-PTX-CLHA NPs. As displayed in 
Figure S14, the cytotoxicity of CAD-PTX-CLHA NPs is significantly reduced, 
revealing that Cys7-HA-C184 molecules possess apparent targeting ability to 
CD44-positive cells. 
Alleviating multidrug resistance with CAD-PTX-CLHA NPs 
To study the possible reasons why CAD-PTX-CLHA NPs are able to alleviate 
drug resistance, the cellular uptake of CAD-PTX-CLHA NPs by MCF-7/ADR cells 
was studied by confocal fluorescence microscopy and flow cytometry. DOX·HCl was 
used as a control group. As shown in Figure 6, A and B, DOX·HCl treated MCF-7/ADR 
cells exhibit red fluorescence signal after 6 h incubation, but the fluorescence 
disappears after 12 h incubation, which is likely due to drug efflux or activation of 
coordinately regulated detoxifying systems in the cells.
37
 In comparison, 
CAD-PTX-CLHA NPs treated MCF-7/ADR cells still display strong fluorescence after 
12 h incubation. When MCF-7/ADR cells were pre-treated with HA before incubation 
with CAD-PTX-CLHA NPs, the fluorescence intensity in the cells becomes very low. 
These data confirm that CAD-PTX-CLHA NPs are uptaken by MCF-7/ADR cells via a 
receptor-mediated mechanism. The quantitative results in Figure 6, C and D showed 
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that the cellular uptake of CAD-PTX-CLHA NPs became stronger over time in 
MCF-7/ADR cells, while poor uptaken was found when MCF-7/ADR cells were 
pre-treated with HA, further back up the above findings.  
In addition, reactive oxygen species (ROS) generation in MCF-7/ADR cells 
treated with different drugs were also examined. PTX can interfere with cell 
microtubules to block the cell reduction pathway, resulting in NADPH oxidation and 
increased intracellular ROS.
38
 The decrosslinking of disulfide bonds on the surface of 
CAD-PTX-CLHA NPs would consume intracellular GSH and then improve the level 
of cellular ROS.
39
 Ultimately, the increased intracellular ROS levels will induce cell 
apoptosis.
40
 Due to its importance, the intracellular ROS generation was measured. As 
shown in Figure 6, E, CAD-PTX-CLHA NPs produce a large amount of ROS in 
MCF-7/ADR cells indicated by the strong fluorescence intensity, which is 
substantially higher than that generated in the cells treated with DOX·HCl, PTX and 
DOX+PTX mixture. 
In vivo performance of CAD-PTX-CLHA NPs 
Once we successfully demonstrate the advantages of pH- and redox- dual 
responsive CAD-PTX-CLHA NPs and their high efficacy in inhibiting cancer cells 
including multidrug resistant cells, the next key question is to study whether the NPs 
can effectively work in in vivo animal model. For this purpose, we investigated the 
blood circulation and biodistribution of these NPs and their tumor inhibition capacity in 
mice. The plasma levels of CAD-PTX-CLHA NPs were determined by measuring the 
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DOX amount of blood samples at different time intervals following a single injection of 
CAD-PTX-CLHA NPs in mice. Notably, CAD-PTX-CLHA NPs reveal a significantly 
long blood circulation time with a half-life of approximately 4 h (Figure S15). 
To investigate whether CAD-PTX-CLHA NPs preferentially accumulate in tumor 
region or not, CAD-PTX-CLHA NPs were intravenously injected into MCF-7/ADR 
tumor-bearing BALB/C mice for in vivo imaging. A laser at 488 nm was used as an 
excitation light for DOX. As shown in Figure 7, A, the CAD-PTX-CLHA NPs treated 
mouse displays intense red fluorescence at the tumor site at 24 h after injection. This 
indicates that CAD-PTX-CLHA NPs possess excellent performance in tumor targeting, 
which can also be used for tumor diagnosis. Subsequently, to know the detailed 
biodistribution of these NPs, the fluorescence intensities of various organs were 
monitored at different time intervals after NP injection. As presented in Figure 7, B and 
Figure S16, the mice treated with CAD-PTX-CLHA NPs possess higher levels of 
fluorescence signals in the tumor tissue than other major organs including heart, liver, 
spleen, lung, kidney, stomach and intestine. Collectively, all of these outcomes exhibit 
that CAD-PTX-CLHA NPs have excellent tumor targeting ability, resulting high drug 
accumulation in tumors and potent ability in tumor growth inhibition. 
To investigate the therapeutic performance of CAD-PTX-CLHA NPs, 
MCF-7/ADR tumor bearing nude mice were employed as model animals. The results 
show that the growth of tumor is effectively inhibited by CAD-PTX-CLHA NPs, with a 
tumor volume of 2.06 ± 0.46 fold of the starting value. In contrast, continuous tumor 
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growth has been observed in the mice treated with DOX·HCl (5.42 ± 0.49 fold), PTX 
(5.60 ± 0.50 fold), DOX+PTX mixture (4.76 ± 0.61 fold) and PBS (7.64 ± 0.66 fold) 
(Figure 7, C). 
Importantly, the mice treated with CAD-PTX-CLHA NPs have little change of 
body weight, which is in a sharp contrast to the significant body weight loss for mice 
treated with DOX·HCl, PTX and DOX+PTX mixture (Figure 7, D). 
We further investigated hematoxylin-eosin (H&E) staining of the major organs 
sections (heart, liver, spleen, lung, and kidney) of saline and CAD-PTX-CLHA NPs 
treated mice at 14 days after initial treatment (Figure S17). Compared to saline-treated 
control group, organs sections of CAD-PTX-CLHA NPs treated mice displayed no 
obvious damages or inflammatory lesion. 
Discussion 
With the aim to design pure anticancer NPs with controlled and environmentally 
responsive release for tumor targeted therapy, we prepared a pH-and redox- dual responsive 
DOX and PTX drug NPs. These NPs are relatively stable in neutral pH such as blood stream 
with very low release of drugs. In comparison, at acidic pH and redox environment, drug 
release is significantly increased. These results clearly indicate that CAD-PTX-CLHA NPs 
present a pH and redox responsive drug release characteristic (Figure 3, E and F). 
Intracellular distribution images indicate that the NPs can also be fluorescently monitored 
and used for diagnosis (Figure 4). 
Moreover, CAD-PTX-CLHA NPs exhibit high cytotoxicity to A549 cancer cells 
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(viability of 23%) but low cytotoxicity (viability of 72%) against HEK-293T normal cells 
and A549 cancer cells pre-treated with HA (viability of 67%) (Figure 5, A and B), indicating 
that these NPs are able to target cancer cells with overexpression of CD44 receptor. 
Meanwhile, CAD-PTX-CLHA NPs have higher cytotoxicity (viability of only 10%) than 
DOX (viability of 21%) and PTX (viability of 26%) to HeLa cells at the same drug 
concentrations, revealing it possesses synergistic anticancer efficacy (Figure 5, C). However, 
CAD-PTX-CLHA NPs display less effectiveness than free DOX when against 4T1 cells 
(Figure 5, D), as peri-cellular HA matrix can prevent NPs’ uptake by 4T1 cells.41 
Furthermore, intracellular distribution images show that CAD-PTX-CLHA NPs can 
effectively enter MCF-7/ADR cells and maintain with the cells for a long period of time, 
which may be accounted to the ability of alleviating multidrug resistance (Figure 6). 
When tested in mice, these NPs have a long blood circulation half-life, high 
accumulation in tumors, and ultimately excellent inhibition of multidrug resistant tumor 
growth (Figure 7). Furthermore, H&E staining of the major organs demonstrate that 
CAD-PTX-CLHA NPs process low systemic toxicity, which is good for in vivo antitumor 
applications.  
The excellent tumor inhibition of CAD-PTX-CLHA NPs should be ascribe to their 
collective advantages and characteristics including cancer cell targeting, synergistic therapy 
of DOX and PTX, pH- and redox- dual responsive release, and effective uptake and retention 
in multidrug resistance cells. All results suggest that our CAD-PTX-CLHA NPs process 
great potential for clinical cancer chemotherapy. 
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Additional data related to this manuscript are provided in the Supplementary material. 
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Figure captions 
Figure 1. Synthesis route of (A) CAD-PTX and (B) Cys7-HA-C184. The regions enclosed by 
the blue and red frames represent amide bond and ɑ-ethylenic bond, respectively. DOX: 
doxorubicin; CAD: cis-aconitic anhydride-modified doxorubicin; PTX: paclitaxel; HA: 
hyaluronic acid. 
Figure 2. Schematic illustration of Cys7-HA-C184 coated CAD-PTX NPs for drug delivery. 
CAD-PTX NPs consists of three segments, each defined by the color of its secondary 
structure: red (CAD), purple (amide bond), and blue (PTX).  
Figure 3. Characterization of NPs. (A) SEM and TEM (inset) images of CAD-PTX NPs. 
The scale bar of the inset image indicates 100 nm; (B) DLS size analysis of CAD-PTX NPs, 
CAD-PTX-NCLHA NPs and CAD-PTX-CLHA NPs; (C) The evolution of the sizes of 
different NPs in PBS over a period of 7 days; (D) Amount of free thiol group Cys7-HA-C184 
(pH 8.5) solution as determined by the Ellman’s test; (E, F) Release profiles of DOX from 
CAD-PTX-CLHA NPs and SAD-PTX-CLHA NPs under different conditions in PBS. 
Figure 4. Cellular uptake and intracellular distribution of CAD-PTX-CLHA NPs. 
Fluorescence images of HeLa cells after being incubated with CAD-PTX-CLHA NPs for 
different times (4, 6, 12 and 24 h). The scale bars indicate 20 μm. In the figure, red, green, 
and blue represent NPs, lysosome and nucleus, respectively. 
Figure 5. In vitro cytotoxicity of CAD-PTX-CLHA NPs. (A, B) Comparative in vitro 
cytotoxicity of CAD-PTX-CLHA NPs against HEK-293T normal cells, A549 and HA 
pre-treated A549 cancer cells with 24 and 48 h incubation time; (C, D) Cell viabilities of 
HeLa and 4T1 cells after being incubated with DOX·HCl, PTX, DOX+PTX mixture, 
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CAD-PTX-NCLHA NPs and CAD-PTX-CLHA NPs for 48 h; (E, F) Cell viabilities of 
MCF-7 and MCF-7/ADR cells after being incubated with DOX·HCl, DOX+PTX mixture 
and CAD-PTX-CLHA NPs for 48 h. 
Figure 6. Inhibition of multidrug resistance with CAD-PTX-CLHA NPs. (A, B) Intracellular 
distribution of DOX·HCl, and CAD-PTX-CLHA NPs after incubation with MCF-7/ADR 
cells for 6 and 12 h. Scale bars: 10 μm; (C, D) Flow cytometry analysis of the same groups 
of experiments as shown in (A, B); (E) Reactive oxygen species (ROS) generation in 
MCF-7/ADR cells treated with DOX·HCl, PTX, DOX+PTX mixture, and CAD-PTX-CLHA 
NPs for 12 and 24 h. Scale bars: 20 μm. 
Figure 7. In vivo performance of CAD-PTX-CLHA NPs. (A) In vivo fluorescence image of 
a tumor bearing mouse at 24 h post injection of CAD-PTX-CLHA NPs; (B) Biodistribution 
of CAD-PTX-CLHA NPs; the inset figure is the fluorescence image of major organs at 24 h 
after NP injection; The evolution of tumor volumes (C) and body weight (D) with time after 
mice were administered with saline, DOX·HCl, PTX, DOX+PTX mixture and 
CAD-PTX-CLHA NPs. 
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We covalently conjugate cis-aconitic anhydride-modified doxorubicin and paclitaxel 
(CAD-PTX) and then self-assemble to nanoparticles, followed by coating with crosslinked 
hyaluronic acid (HA) via disulfide bonds. These NPs possesses pH-and redox- dual 
responsive release characteristics. Besides, the drug system is able to target cancer cells with 
overexpression of CD44 receptor and possesses potent toxicity to multidrug resistant cells. 
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